Study to Evaluate DNL747 in Subjects With Alzheimer's Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL747 in subjects with Alzheimer's disease when administered for 29 days in a cross-over design

Key facts

Study ID

NCT03757325

Run by

Denali Therapeutics Inc.

People needed

16

Starts

2019-02-13

Expected to finish

2019-12-05

Last updated by the study team

2020-02-26

Who can join

Age: 55 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Clinical Site(s) — Miami, Florida, United States
• Clinical Site(s) — Orlando, Florida, United States
• Clinical Site(s) — Dallas, Texas, United States
• Clinical Site(s) — Salt Lake City, Utah, United States
• Clinical Site(s) — Groningen, Netherlands

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.